Ben-Ishay Z, Prindull G, Sharon S
Department of Anatomy and Embryology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Leuk Res. 1991;15(5):321-5. doi: 10.1016/0145-2126(91)90007-g.
Acute myeloid leukemia (AML) was induced in C57Bl mice through the i.v. innoculation of C-1498 cell line. One week later, i.e. at mid-term disease, the leukemic mice received an i.p. injection of 200 ng rmGM-CSF and 24 h later, two consecutive i.p. cytosine arabinoside (ara-C) injections at 6 h intervals (2 x 200 mg/kg). The leukemic mice received 3-4 weekly courses of combined therapy and survived 4-5 weeks following leukemia induction. Control mice received ara-C only and survived 2-3 weeks. Moreover, leukemic mice administered both GM-CSF and ara-C had a lower marrow leukemic load than mice treated with ara-C only. From these findings, we conclude that therapy of murine AML with combined rmGM-CSF and ara-C is more effective than ara-C only. Leukemic mice treated with GM-CSF and ara-C had a longer life expectancy and a smaller leukemic load than mice administered ara-C only.
通过静脉注射C - 1498细胞系在C57Bl小鼠中诱导急性髓系白血病（AML）。一周后，即在疾病中期，白血病小鼠腹腔注射200 ng重组人粒细胞巨噬细胞集落刺激因子（rmGM - CSF），24小时后，每隔6小时连续两次腹腔注射阿糖胞苷（ara - C）（2×200 mg/kg）。白血病小鼠接受3 - 4个每周疗程的联合治疗，白血病诱导后存活4 - 5周。对照小鼠仅接受阿糖胞苷治疗，存活2 - 3周。此外，同时给予GM - CSF和阿糖胞苷的白血病小鼠骨髓白血病负荷低于仅用阿糖胞苷治疗的小鼠。从这些发现中，我们得出结论，联合rmGM - CSF和阿糖胞苷治疗小鼠AML比仅用阿糖胞苷更有效。与仅给予阿糖胞苷的小鼠相比，接受GM - CSF和阿糖胞苷治疗的白血病小鼠预期寿命更长，白血病负荷更小。
